Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (261-270 of 324) with videos related to

Pageof 33
Sort By:
RNA Biology|September 30, 2011
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specificKazuo Suzuki, Takaomi Ishida, Makoto Yamagishi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 16, 2012
Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expressionSanjay Swaminathan, Kazuo Suzuki, Nabila Seddiki, et al.
Current Opinion in HIV and AIDS|October 28, 2010
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in AsiaSupachai Rerks-Ngarm, Punnee Pitisuttithum, Nirmal Ganguly, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 studyPeter G Cardiello, Rolf P van Heeswijk, Elly A Hassink, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2006
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)Mark T Bloch, Don E Smith, Dick Quan, et al.
Blood|May 21, 2005
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infectionJohn J Zaunders, Mee Ling Munier, Daniel E Kaufmann, et al.
Tuberculosis (Edinburgh, Scotland)|May 1, 2012
A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assaysDenise C Hsu, John J Zaunders, Marshall Plit, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Pageof 33

Showing results (261-270 of 324) with videos related to

Sort By:
Pageof 33
RNA Biology|September 30, 2011
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specificKazuo Suzuki, Takaomi Ishida, Makoto Yamagishi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 16, 2012
Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expressionSanjay Swaminathan, Kazuo Suzuki, Nabila Seddiki, et al.
Current Opinion in HIV and AIDS|October 28, 2010
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in AsiaSupachai Rerks-Ngarm, Punnee Pitisuttithum, Nirmal Ganguly, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2002
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 studyPeter G Cardiello, Rolf P van Heeswijk, Elly A Hassink, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2006
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)Mark T Bloch, Don E Smith, Dick Quan, et al.
Blood|May 21, 2005
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infectionJohn J Zaunders, Mee Ling Munier, Daniel E Kaufmann, et al.
Tuberculosis (Edinburgh, Scotland)|May 1, 2012
A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assaysDenise C Hsu, John J Zaunders, Marshall Plit, et al.
Plos One|February 28, 2015
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Pageof 33